P/F Bakkafrost (BKFKY) Q1 2026 Earnings Call Transcript

Bakkafrost reported Q1 2026 revenue up 11% year over year to about NOK 2.1 billion and operational EBIT up 8% to NOK 544 million, despite lower year-on-year prices and higher global supply. Faroes harvest volumes rose 33% to roughly 25,100 tonnes gutted weight, while Scotland volumes were broadly stable at around 6,200 tonnes. Cash flow from operations fell to DKK 453 million from DKK 590 million, and the AGM approved a DKK 3.45 dividend payment.

Analysis

The key signal here is not the modest earnings beat; it is the asymmetry between harvest growth and cash conversion. A 33% step-up in Faroe volumes with only 8% EBIT growth implies unit economics are being partially diluted by weaker pricing and/or a higher-cost mix, which is exactly the setup where the market tends to over-penalize near-term earnings power while underestimating the compounding benefit of scale if biology remains intact.

The second-order winner is the feed and input ecosystem, because stronger biological growth typically pulls through higher demand for feed, logistics, processing, and husbandry services before it fully shows up in reported margins. The loser is the broader salmon supply basket: if Bakkafrost can add volume into a softer price tape, it adds incremental supply discipline pressure for peers that lack comparable biological momentum, especially those with more leverage to spot pricing and weaker balance sheets.

The cash flow decline versus the prior year is more important than the headline EBIT move because it raises the probability that the market will focus on free cash flow quality rather than operating momentum. That matters for capital return: a dividend can support the stock over days, but if working capital or investment intensity stays elevated for multiple quarters, the payout becomes a secondary rather than primary valuation anchor. This is a months-long debate, not a one-day event.

The contrarian view is that the market may be too anchored to lower salmon prices and missing the optionality in volume normalization. If biology continues to improve, Bakkafrost can still lever operating profit on future price stabilization; the setup is more attractive than it looks because the stock is effectively being offered a call option on pricing recovery with current operations paying the premium.

Key Decisions for Investors

• Go long BKFKY on a 1-3 month horizon into any post-earnings weakness; target a re-rating if investors shift from price-led to volume-led valuation, with downside limited by dividend support and upside tied to another quarter of biological outperformance.
• Pair trade: long BKFKY / short a higher-beta salmon producer with weaker biological visibility over the next 2-4 quarters; the thesis is that volume resilience matters more than headline price pressure when the cycle is soft.
• Reduce exposure to names leveraged to salmon spot pricing if they lack similar volume growth or dividend support; the risk is that incremental supply from efficient growers keeps near-term pricing depressed for several quarters.
• For income-oriented mandates, hold BKFKY through the dividend ex-date but reassess after the next quarterly cash conversion update; if operating cash flow remains below EBIT progression, the stock could de-rate on payout sustainability concerns.